Partners Wealth Management LLC Acquires New Position in AbbVie Inc. $ABBV

Posted by Brenda Bartman on Nov 1st, 2026

Partners Wealth Management LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,631 shares of the company’s stock, valued at approximately $688,000.

A number of other institutional investors and hedge funds have also modified their holdings of ABBV. Ranch Capital Advisors Inc. grew its position in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after acquiring an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK raised its position in AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after purchasing an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in AbbVie in the second quarter worth $23,557,000. Wedge Capital Management L L P NC boosted its stake in AbbVie by 7.5% in the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after purchasing an additional 9,380 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $294.80 on Friday. The company has a market cap of $520.85 billion, a price-to-earnings ratio of 50.74, a P/E/G ratio of 1.35 and a beta of 0.24. The stock’s fifty day moving average price is $269.35 and its two-hundred day moving average price is $237.23. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $298.74.

AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The company had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $1.86 EPS. On average, equities analysts predict that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.3%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Bank of America reiterated a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and increased their price objective for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. Barclays increased their price objective on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a report on Wednesday, October 21st. Finally, The Goldman Sachs Group raised their price objective on shares of AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research report on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $279.86.

Get Our Latest Analysis on AbbVie

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

About AbbVie

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.